Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Outcomes of splenectomy in benign and malignant hematologic conditions in the immunotherapy era

View Full Paper
Ask AI
Bookmark
Share

Authors

JRJohn Rutledge

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals reduced splenectomies and changing complication rates in leukemia and lymphoma with immunotherapy advancement.

Key Points

  • Splenectomy rates for hematologic conditions significantly declined due to FDA approval of immunotherapies, reflecting improved disease management.
  • Infectious complications in leukemia cases rose significantly, with a notable decrease in perioperative bleeding for lymphoma patients.
  • Retrospective cohort study used NSQIP database, highlighting substantial trends in surgical practices and outcomes from 2012 to 2023.
  • Findings emphasize the need for further patient-level studies to fully understand the impacts of immunotherapy on surgical risk.

Cite This Study

John Rutledge (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236dfe6https://doi.org/10.1182/blood-2025-4462
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pediatric splenectomy for hematologic disorders: two-decade experience and prophylactic cholecystectomy outcomes2025
  2. 2Efficacy and Complications of Open vs. Laparoscopic Splenectomy: A Systematic Review2025 · 1 citations
  3. 3Assessment of thrombotic risk and pathophysiological mechanisms of splenectomy-associated hypercoagulability in patients with immune thrombocytopenia2025
  4. 4Subtotal Versus Total Splenectomy in Children With Sickle Cell Disease: Clinical Outcomes and Splenic Function Assessed by Pocked Red Blood Cell Count2025
  5. 5Long-term complications of splenectomy in dogs with benign splenic disease are not associated with mortality2025